Effect of Benralizumab on Airway Remodeling in Asthma (BENRAMOD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Pierre-Olivier GIRODET, MD, PhD
- Phone Number: +33 5 57 62 31 94
- Email: pierre-olivier.girodet@u-bordeaux.fr
Study Contact Backup
- Name: Karelle FOREST
- Phone Number: +33 5 57 62 31 94
- Email: Karelle.FOREST@u-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France, 33604
- Recruiting
- CIC-P - Centre François Magendie - G3 - Hôpital Haut-Lévêque
-
Contact:
- Pierre-Olivier GIRODET, MD, PhD
- Phone Number: +33 (0)5 57 62 31 94
- Email: pierre-olivier.girodet@chu-bordeaux.fr
-
Principal Investigator:
- Pierre-Olivier GIRODET, MD, PhD
-
Sub-Investigator:
- Patrick BERGER, MD, PhD
-
Contact:
- Karelle FOREST
- Phone Number: +33 (0)5 57 62 31 94
- Email: Karelle.FOREST@u-bordeaux.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Healthy subjects
- Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
- Age higher than 18 years.
- No prior history of any chronic respiratory disease including asthma.
- No prior history of allergy, i.e. allergic rhinitis, allergic conjunctivitis, hay fever, eczema.
- No clinically significant abnormalities as determined by medical history, measurement of vital signs, physical examination, hematologic assessments and ECG at visit 1.
- Normal lung function with FEV1 > 90%.
Non-severe asthmatics subjects
- • Written informed consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
- Age higher than 18 years.
- Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA), i.e. GINA steps 1, 2 or 3 (18).
- Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment, or PC20 methacholine < 16 mg/mL documented within 12 months prior to screening.
- Documented blood eosinophils ≥300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1.
Severe asthmatics subjects
- • Written inform consent indicating that they understand the purpose and procedures required for the study and are willing to participate in the study.
- Age higher than 18 years.
- Diagnosis of severe asthma according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) task force (19).
- Documented post-bronchodilator reversibility of at least 12% and at least 200 mL in FEV1 within 12 months before enrolment.
- Documented blood eosinophils ≥300 cells per μL within 12 months or blood eosinophils ≥150 cells per μL at visit 1.
Exclusion Criteria:
- Active smoker or former smoker.
- Diagnosis of chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
- CT scan abnormality related to any respiratory disease other than asthma.
- Recent asthma exacerbation (less than 6 weeks before bronchoscopy).
Contraindications related to bronchoscopy:
- coagulation disorders,
- unstable cardiovascular conditions,
- FEV1 lower than 1 litter,
- a fasting state of less than 6 hours for food and less than 2 hours for drink.
- Contraindications to general anesthesia or medications (for propofol: hypersensitivity to the active substance and to any of the excipients; for lidocaine: hypersensitivity to the active substance and to any of the excipients or to local anesthetics of the amide type, epilepsy, porphyria) used in the bronchoscopy procedure.
Contraindications related to MRI:
- Pacemaker or implantable cardioverter defibrillator
- Metallic foreign body in the eye
- Cerebral aneurysm clips
- Insulin pumps
- Claustrophobia
- Positive urinary pregnancy test at screening for women of child-bearing potential
- Breastfeeding woman.
- Previously received benralizumab.
- History of any clinically significant medical illness or medical disorders including (but not limited to) cardiovascular disease, neuromuscular, hematological disease including bleeding disorders, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
- Recent history (within previous 6 months) of alcohol or drug abuse.
- Persons placed under judicial protection.
- Persons participating in another research including a period of exclusion still in course.
- Severely altered physical and/or psychological health which, according to, the investigator, could affect the participant's compliance of the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
severe asthma
|
Endobronchial biopsies will be collected following a standardized procedure based on established guidelines.
Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure.
Anesthesia of the upper airways will be achieved with lidocaine 5% spray.
The total amount of lidocaine per subject is limited to 225 mg.
General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg).
The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe.
Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed.
The duration of bronchoscopy is 15 minutes to 30 minutes.
After the procedures, subjects will receive a short acting bronchodilator if required.
|
|
non-severe asthma
• Diagnosis of non-severe asthma according to the Global Initiative for Asthma (GINA).
|
Endobronchial biopsies will be collected following a standardized procedure based on established guidelines.
Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure.
Anesthesia of the upper airways will be achieved with lidocaine 5% spray.
The total amount of lidocaine per subject is limited to 225 mg.
General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg).
The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe.
Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed.
The duration of bronchoscopy is 15 minutes to 30 minutes.
After the procedures, subjects will receive a short acting bronchodilator if required.
|
|
non-asthmatic controls
|
Endobronchial biopsies will be collected following a standardized procedure based on established guidelines.
Before the procedure, asthmatic subjects will receive 400 μg of salbutamol with the aid of an aerosol chamber to open up the airways before the procedure.
Anesthesia of the upper airways will be achieved with lidocaine 5% spray.
The total amount of lidocaine per subject is limited to 225 mg.
General anesthesia will be obtained using propofol (average dose of 1.5 to 2 mg/kg).
The fiberoptic bronchoscope (Pentax BF 15V, Argenteuil, France) is introduced and 8 to 10 biopsies will be taken from the middle lobe and the lower right lobe.
Standard procedures such as bronchial brushing and bronchial fluid aspiration will also be performed.
The duration of bronchoscopy is 15 minutes to 30 minutes.
After the procedures, subjects will receive a short acting bronchodilator if required.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Bronchial smooth muscle (BSM) cells obtained from severe asthmatics measured in vitro using BrdU incorporation.
Time Frame: Month 12
|
Determine the proliferation of BSM cells obtained from severe asthmatics measured in vitro using BrdU incorporation.
|
Month 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of cultured BSM cell from non-severe asthmatics and healthy volunteers measured using BrdU incorporation.
Time Frame: Month 12
|
Determine the proliferation of cultured BSM cell from non-severe asthmatics and healthy volunteers measured using BrdU incorporation.
|
Month 12
|
|
Number of different genes
Time Frame: Month 12
|
Gene expression within BSM cells (RT-PCR, nCCounter Immunology panels)
|
Month 12
|
|
Measure the inflammatory mediators and extracellular components
Time Frame: Month 12
|
Production of inflammatory mediators and extracellular components by cultures BSM cells (ELISA, bio-Plex® Multiples Immunoassays)
|
Month 12
|
|
Measure the fluorescence intensity of IL-5 receptor subunit alpha on BSM cells
Time Frame: Month 12
|
Determine of expression of IL-5 receptor subunit alpha on BSM cells (% of positive cells, mean fluorescence intensity) using flow cytometry
|
Month 12
|
|
Count the number of mitochondria / BSM area (x107/mm2)
Time Frame: Month 12
|
Determine of number of mitochondria / BSM area (x107/mm2) and mitochondrial density using electron microscopy
|
Month 12
|
|
Count the number of eosinophils/smooth muscle area using optic microscopy
Time Frame: Month 12
|
Histological criteria: BSM area (% of tissue area), number of eosinophils/smooth muscle area using optic microscopy
|
Month 12
|
|
Measure the bronchial dimension by CT-scan
Time Frame: Month 12
|
Bronchial dimensions assessed by CT-scan
|
Month 12
|
|
Measure the bronchial dimension by MRI
Time Frame: Month 12
|
Bronchial dimensions assessed by MRI
|
Month 12
|
|
Measure the lung low single intensity and low attenuation values using MRI
Time Frame: Month 12
|
Determine the Lung low single intensity and low attenuation values using MRI
|
Month 12
|
|
Measure the lung low single intensity and low attenuation values using CT-scan
Time Frame: Month 12
|
Determine the Lung low single intensity and low attenuation values using CT-scan
|
Month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Pierre-Olivier GIRODET, MD, PhD, University Hospital, Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2019/34
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.